Chronic Inflammatory Demyelinating Polyneuropathy Market Size (US) was ~USD 1,382 Million in 2023 and It is projected to grow by 2034, estimates DelveInsight

DelveInsight's "Chronic Inflammatory Demyelinating Polyneuropathy Market Insight, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of desmoid tumor, historical and forecasted epidemiology as well as the Chronic Inflammatory Demyelinating Polyneuropathy market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Unlock key insights into the Chronic Inflammatory Demyelinating Polyneuropathy Market! Download DelveInsight's comprehensive report to explore market trends, pipeline analysis, and emerging therapies @ Chronic Inflammatory Demyelinating Polyneuropathy Market Size- https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Chronic Inflammatory Demyelinating Polyneuropathy Market Report
• In 2023, the US accounted for the highest diagnosed prevalent cases of CIDP with approximately 30,230 cases, which are expected to increase by 2034.
• Among EU4 and the UK, the UK had the highest diagnosed prevalent cases of CIDP, with nearly 3,250 cases in 2023, followed by Germany with around 3,174 cases. In contrast, Spain has the lowest number, with nearly 1,691 cases.
• In 2023, Japan accounted for approximately 2,045 diagnosed prevalent cases of CIDP which are expected to increase by 2034.
• In 2023, among the subtype-specific cases of CIDP, the US accounted for approximately 15,417 cases for typical CIDP and 14,813 cases for atypical CIDP.
• In 2023, Germany had approximately 2,380 males and 793 females diagnosed with CIDP.
• In 2023, the diagnosed prevalent cases of CIDP across the age groups 0-19 years, 20-39 years, 40-59 years, 60-79 years and 80 years and older were approximately 41, 82, 798, 900 and 225, respectively, in Japan.
• The leading Chronic Inflammatory Demyelinating Polyneuropathy Companies such as CSL Behring, Grifols, Kedrion Biopharma, Nihon Pharmaceutical, LFB, Teijin Pharma, OctaPharma, Shire, Takeda, UCB Biopharma, MedDay Pharmaceuticals, GeNeuro Pharmaceuticals, Pfizer, argenx, Momenta Pharmaceuticals, among others.
• Promising Chronic Inflammatory Demyelinating Polyneuropathy Therapies such as Riliprubart, Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly, Efgartigimod PH20 SC, SAR445088 (IV), and others.

Stay ahead in the competitive landscape of the Chronic Inflammatory Demyelinating Polyneuropathy Market. Access DelveInsight's in-depth market analysis and strategic insights today! Click here for more @ Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market Size- https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology Segmentation in the 7MM
• Diagnosed Prevalent Cases
• Gender-specific Diagnosed Prevalent Cases
• Age-specific Diagnosed Prevalent Cases
• Clinical Subtype-specific Diagnosed Prevalent Cases
• Refractory Cases

Download the report to understand which factors are driving Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology trends @ Chronic Inflammatory Demyelinating Polyneuropathy Prevalence- https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Marketed Chronic Inflammatory Demyelinating Polyneuropathy Drugs
• HYQVIA (Immune Globulin Infusion 10% [Human] with Recombinant Human Hyaluronidase): Takeda
HYQVIA is an immunostimulant combining human immunoglobulin (IG 10%) with recombinant human hyaluronidase, enabling SC for easier administration. This treatment offers a convenient alternative to IVIg by allowing larger-volume, less frequent SC due to enhanced absorption. HYQVIA modulates the immune system to reduce autoimmune damage to the nerves in CIDP. In January 2024, the US FDA approved HYQVIA for the maintenance treatment of CIDP in adults. The European Commission also approved it for the same purpose, and the UK's MHRA granted approval in March 2024. Takeda filed for approval in Japan in August 2024.

• VYVGART HYTRULO (Efgartigimod Alfa and Hyaluronidase-Qvfc): Argenx
VYVGART HYTRULO is a coformulation of efgartigimod alfa and recombinant human hyaluronidase, designed to enhance SC absorption. It works by reducing autoantibodies implicated in CIDP through inhibition of the FcRn receptor. Approved by the US FDA in June 2024, it received orphan drug designation for CIDP in 2021. This therapy offers a convenient option for maintaining remission via SC administration.

• GAMMAGARD LIQUID/KIOVIG (Immune Globulin Infusion [Human] 10% Solution): Takeda
GAMMAGARD LIQUID/KIOVIG is a ready-to-use IV formulation of IVIg derived from human plasma, offering a broad spectrum of antibodies. It works by modulating the immune system, reducing inflammation, and preventing further nerve damage in CIDP. Clinical studies have shown its effectiveness in improving muscle strength and functional ability, helping manage symptoms and maintain long-term stability. It was approved by the US FDA in January 2024 for adults with CIDP. In May 2019, KIOVIG was also approved in the EU for treating CIDP in adults, children, and adolescents (0-18 years).

Chronic Inflammatory Demyelinating Polyneuropathy Emerging Drugs
• Riliprubart (SAR445088): Sanofi
Riliprubart (SAR445088) is an investigational IgG4 humanized monoclonal antibody designed to block activated C1s, a key component of the classical complement pathway. By inhibiting C1s, it aims to reduce inflammation and prevent nerve damage in CIDP. Currently in Phase III, riliprubart targets CIDP patients resistant to standard treatments or IVIg. The FDA granted ODD in July 2021. Submission timelines for CIDP treatment are projected for completion by 2026.

• Nipocalimab: Janssen Research and Development
Nipocalimab (JNJ-80202135) is an investigational monoclonal antibody that acts as an FcRn inhibitor, administered IV. It targets harmful IgG antibodies, without broadly suppressing the immune system. It is in Phase II/III trials for CIDP. In October 2021, the US FDA granted ODD to nipocalimab for its potential use in treating CIDP. Additionally it is anticipated that the ongoing trials of nipocalimab could be pivotal in shaping its clinical potential in the realm of CIDP treatment.

• Batoclimab (HL161): Immunovant Sciences GmbH/HanAll Pharma/Roivant Sciences
Batoclimab (HL161) is a fully human monoclonal antibody targeting FcRn, developed as a SC injection for autoimmune diseases driven by IgG antibodies, including CIDP. It works by inhibiting FcRn, promoting IgG breakdown and reducing its levels. Currently in Phase II trials for CIDP, top-line results are expected by March 2025. Batoclimab's data will guide the design of future trials and regulatory approval for CIDP therapies.

Discover the future of Chronic Inflammatory Demyelinating Polyneuropathy Treatments with DelveInsight's latest market report. Get expert insights and forecasts-download now! @ Chronic Inflammatory Demyelinating Polyneuropathy Market Drivers and Barriers- https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Chronic Inflammatory Demyelinating Polyneuropathy Market Outlook
Chronic inflammatory demyelinating polyneuropathy, though classified as a rare disease, has gained increasing recognition in recent years. This is largely due to improvements in diagnostic techniques, greater awareness among healthcare professionals, and a deeper understanding of the condition. Management of CIDP typically involves a combination of pharmacological therapies and supportive interventions, with the primary objectives to suppress inflammation, modulate immune responses, and improve motor and sensory function.

Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market
The treatment landscape for CIDP has advanced with a multi-faceted approach, combining medications, and supportive care. Corticosteroids, such as prednisone and dexamethasone, are often the initial treatment. While they are effective in inducing remission, they carry a high risk of significant long-term side effects, including osteoporosis, weight gain, and increased susceptibility to infections. These adverse effects often necessitate combination therapies with steroid-sparing agents, which may not be universally effective. Plasma exchange has shown short-term efficacy in removing harmful autoantibodies and improving symptoms. However, it is an invasive procedure that requires highly specialized centers and trained personnel, limiting its accessibility, IVIg has become the gold standard due to its demonstrated efficacy in long-term disease control and symptom improvement. Despite this, IVIg is costly, time-consuming, and heavily reliant on donor plasma, raising concerns about its long-term availability.

Explore the dynamics of the Chronic Inflammatory Demyelinating Polyneuropathy Market with DelveInsight. From market size to emerging drugs-find it all in our latest report. Read now! @ Chronic Inflammatory Demyelinating Polyneuropathy Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Chronic Inflammatory Demyelinating Polyneuropathy Market Report
• Coverage- 7MM
• Study Period- 2020-2034
• Chronic Inflammatory Demyelinating Polyneuropathy Companies- CSL Behring, Grifols, Kedrion Biopharma, Nihon Pharmaceutical, LFB, Teijin Pharma, OctaPharma, Shire, Takeda, UCB Biopharma, MedDay Pharmaceuticals, GeNeuro Pharmaceuticals, Pfizer, argenx, Momenta Pharmaceuticals, among others.
• Chronic Inflammatory Demyelinating Polyneuropathy Therapies- Riliprubart, Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly, Efgartigimod PH20 SC, SAR445088 (IV), and others.
• Chronic Inflammatory Demyelinating Polyneuropathy Market Dynamics: Chronic Inflammatory Demyelinating Polyneuropathy Market Drivers and Barriers
• Chronic Inflammatory Demyelinating Polyneuropathy Market Access and Reimbursement, Unmet Needs and Future Perspectives

Table of Contents
1. Key Insights
2. Chronic Inflammatory Demyelinating Polyneuropathy Market Report Introduction
3. Chronic Inflammatory Demyelinating Polyneuropathy Executive Summary
4. Key Events
5. Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology and Market Forecast Methodology
6. Chronic Inflammatory Demyelinating Polyneuropathy Market Overview at a Glance
7. Chronic Inflammatory Demyelinating Polyneuropathy Market Disease Background and Overview
8. Guidelines
9. Epidemiology and Patient Population of Chronic Inflammatory Demyelinating Polyneuropathy in the 7MM
10. Chronic Inflammatory Demyelinating Polyneuropathy Patient Journey
11. Chronic Inflammatory Demyelinating Polyneuropathy Marketed Drugs
12. Chronic Inflammatory Demyelinating Polyneuropathy Emerging Drugs
13. Chronic Inflammatory Demyelinating Polyneuropathy: 7MM Analysis
14. Chronic Inflammatory Demyelinating Polyneuropathy Unmet Needs
15. Chronic Inflammatory Demyelinating Polyneuropathy SWOT Analysis
16. Chronic Inflammatory Demyelinating Polyneuropathy KOL Views
17. Chronic Inflammatory Demyelinating Polyneuropathy Market Access and Reimbursement
18. Appendix
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.